--- title: "Fennec Pharmaceuticals (FENC) news: convertible notes and lawsuit" url: "https://aibio.space/companies/fennec-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "FENC convertible notes, lawsuit and settlement news: Fennec Pharmaceuticals repays $13 million of convertible debt early. Fennec Pharmaceuticals Inc." --- FENC Fennec Pharmaceuticals Inc. NASDAQ · United States # Fennec Pharmaceuticals (FENC) news FENC convertible notes, lawsuit and settlement news Legal · 2026-03-16 ## [Fennec Pharmaceuticals settles PEDMARK patent litigation with Cipla](https://aibio.space/news/fennec-pharmaceuticals-settles-pedmark-patent-litigation-cipla/) Under a license agreement, the lawsuit will be dismissed and Cipla will not sell a generic version in the U.S. until September 1, 2033, or earlier under specified circumstances. Each side bears its own costs. ## Latest Fennec Pharmaceuticals news 1. 2024-12-20 Financings [Fennec Pharmaceuticals repays $13 million of convertible debt early](https://aibio.space/news/fennec-pharmaceuticals-repays-13-million-convertible-debt-early/) The payment to Petrichor comes from available cash. It cuts about $1.5 million in annual interest and removes about 1.6 million potential shares. ## Fennec Pharmaceuticals at a glance - **Ticker**: FENC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $41.2 million ### Related companies - [Edgewise Therapeutics](https://aibio.space/companies/edgewise-therapeutics/) NASDAQ: EWTX - [Phio Pharmaceuticals](https://aibio.space/companies/phio-pharmaceuticals/) NASDAQ: PHIO - [BioCardia](https://aibio.space/companies/biocardia/) NASDAQ: BCDA - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) NASDAQ: VERA - [Aditxt](https://aibio.space/companies/aditxt/) OTC: ADTX - [Rani Therapeutics Holdings](https://aibio.space/companies/rani-therapeutics/) NASDAQ: RANI - [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) NASDAQ: SABS - [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) NASDAQ: KYTX ### Also on NASDAQ - [Longeveron](https://aibio.space/companies/longeveron/) LGVN - [MapLight Therapeutics](https://aibio.space/companies/maplight-therapeutics/) MPLT - [Sarepta Therapeutics](https://aibio.space/companies/sarepta-therapeutics/) SRPT - [Exelixis](https://aibio.space/companies/exelixis/) EXEL - [Ovid Therapeutics](https://aibio.space/companies/ovid-therapeutics/) OVID - [Korro Bio](https://aibio.space/companies/korro-bio/) KRRO ## What Fennec Pharmaceuticals does Fennec Pharmaceuticals is a biopharmaceutical company that describes itself as a single product company, with PEDMARK as its only product. PEDMARK has received marketing approval from the U.S. Food and Drug Administration and from the European Commission, but not from any other foreign authorities. The company says it has only recently transitioned from a development stage biopharmaceutical company to a commercial stage company, and it reports a history of significant losses and limited revenue from product sales. Its strategy depends in part on third-party development partners that seek approvals and commercialize PEDMARK outside the United States: Norgine Pharma UK Limited in Europe, and Inpharmus, formerly TRPharm, in Turkey and Gulf Cooperation Council countries. The company says PEDMARK targets diseases with small patient populations. It relies on third parties to supply raw materials, conduct clinical trials and manufacture PEDMARK, and it notes that it may be required to conduct additional clinical trials for PEDMARK. The company also holds orphan drug exclusivity considerations under review by regulators. | Product or program | What it is | Stage | |---|---|---| | PEDMARK | Only product; targets diseases with small patient populations | Approved by the FDA and the European Commission | Summarised from the company's [10-K filed Mar 27, 2026](https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/fencf-20251231x10k.htm). ## Fennec Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$44.6 million](https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/) | [$47.5 million](https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/) | | Research and development | [$250,000](https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/) | [$307,000](https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/) | | Net income (loss) | [-$9.7 million](https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/) | [-$436,000](https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/) | | Cash from operations | [-$12.5 million](https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/) | [$27.0 million](https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/) | | Cash and equivalents | [$36.8 million](https://www.sec.gov/Archives/edgar/data/1211583/000110465926095884/) | [$26.6 million](https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $41.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Fennec Pharmaceuticals Has Fennec Pharmaceuticals sold convertible notes? Our latest story on this, dated Dec 20, 2024: "Fennec Pharmaceuticals repays $13 million of convertible debt early". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fennec-pharmaceuticals-repays-13-million-convertible-debt-early/). Is Fennec Pharmaceuticals involved in a lawsuit? Our latest story on this, dated Mar 16, 2026: "Fennec Pharmaceuticals settles PEDMARK patent litigation with Cipla". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fennec-pharmaceuticals-settles-pedmark-patent-litigation-cipla/). Has Fennec Pharmaceuticals settled a lawsuit? Our latest story on this, dated Mar 16, 2026: "Fennec Pharmaceuticals settles PEDMARK patent litigation with Cipla". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fennec-pharmaceuticals-settles-pedmark-patent-litigation-cipla/). What is the ticker symbol of Fennec Pharmaceuticals? Fennec Pharmaceuticals Inc. trades under the ticker FENC on NASDAQ. Where is Fennec Pharmaceuticals listed? Fennec Pharmaceuticals Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:RV41; LS:A12A5F; TSX:FRX. What is the SEC CIK of Fennec Pharmaceuticals? The SEC Central Index Key (CIK) for Fennec Pharmaceuticals Inc. is 1211583. Its filings are on SEC EDGAR. How many shares does Fennec Pharmaceuticals have outstanding? 35,067,159 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Fennec Pharmaceuticals listed under? Our directory records Fennec Pharmaceuticals Inc. under United States. What does Fennec Pharmaceuticals do? Our directory classifies Fennec Pharmaceuticals Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Fennec Pharmaceuticals? The ISIN recorded for Fennec Pharmaceuticals Inc. is CA31447P1009. Does aibio.space cover Fennec Pharmaceuticals? aibio.space lists Fennec Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Fennec Pharmaceuticals incorporated? SEC records list its state or country of incorporation as A1. What does Fennec Pharmaceuticals develop? Fennec Pharmaceuticals is a biopharmaceutical company that describes itself as a single product company, with PEDMARK as its only product. PEDMARK has received marketing approval from the U.S. Food and Drug Administration and from the European Commission, but not from any other foreign authorities. What is PEDMARK from Fennec Pharmaceuticals? PEDMARK: Only product; targets diseases with small patient populations Stage: Approved by the FDA and the European Commission. What was Fennec Pharmaceuticals's revenue last year? $44.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Fennec Pharmaceuticals Members talk about Fennec Pharmaceuticals (FENC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Fennec Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2025-11-13 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1211583/000110465925111305/tm2531139d1_424b5.htm) 2. 2024-12-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1211583/000110465924130854/tm2431725d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:FENC on TradingView](https://www.tradingview.com/symbols/NASDAQ-FENC/). ## SEC filings and registration - **SEC name**: Fennec Pharmaceuticals Inc. - **CIK**: 1211583 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: FENC (Nasdaq) - **State or country of incorporation**: A1 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: PO BOX 13628, RESEARCH TRIANGLE PARK, NC, 27709 - **Phone**: (919) 636-4530 - **Shares outstanding**: 35,067,159 as of 2026-08-11 (10-Q filed 2026-08-13) - **Former names**: ADHEREX TECHNOLOGIES INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465926108565/fencf-20260917x8k.htm) filed 2026-09-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1211583/000110465926095884/fencf-20260630x10q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465926072425/tm2617550d1_8k.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465926065696/fencf-20260521x8k.htm) filed 2026-05-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465926063271/fencf-20260518x8k.htm) filed 2026-05-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1211583/000110465926061213/fencf-20260331x10q.htm) filed 2026-05-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465926050433/fencf-20260427x8k.htm) filed 2026-04-28 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1211583/000110465926050339/fencf-20260610xdef14a.htm) filed 2026-04-28 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001211583), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Fennec Pharmaceuticals Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FENC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Fennec Pharmaceuticals Inc. - **Ticker**: FENC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: CA31447P1009 - **Other listed symbols**: GETTEX:RV41; LS:A12A5F; TSX:FRX - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-FENC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/fennec-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Fennec Pharmaceuticals (FENC) news: convertible notes and lawsuit", 2026-10-31, https://aibio.space/companies/fennec-pharmaceuticals/